Technology
Health
Biotechnology
Ultragenyx Pharmaceutical
$64.659876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$64.65
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$4.39 (-6.36%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell RARE and other stocks, options, ETFs, and crypto commission-free!
About
Ultragenyx Pharmaceutical Inc. Common Stock, also called Ultragenyx Pharmaceutical, is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Read More Its product includes Mepsevii and Crysvita. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.
Employees
610
Headquarters
Novato, California
Founded
2010
Market Cap
3.51B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
543.14K
High Today
$68.88
Low Today
$64.56
Open Price
$68.42
Volume
298.96K
52 Week High
$90.98
52 Week Low
$37.44
Collections
Technology
Health
Biotechnology
Pharmaceutical
Biopharmaceutical
2014 IPO
US
North America
News
MarketBeatMar 10
Stock Price, News, & Analysis for Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII. The company is developing various biologics product candidates, including Burosumab, a human monoclonal antibody that ...
Price Paid on Robinhood
11% Higher
Right Now
52 Week Low
$37.44
Average Price Paid
$58.15
52 Week High
$90.98
Earnings
-$2.09
-$1.46
-$0.84
-$0.21
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected May 6, After Hours